Seda Gulec Yilmaz1, Faruk Yencilek2, Asif Yildirim3, Esin Yencilek4, Turgay Isbir5. 1. Department of Molecular Medicine, Institute of Health Sciences, Yeditepe University, Istanbul, Turkey. 2. Department of Urology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. 3. Department of Urology, Göztepe Education and Research Hospital, Istanbul, Turkey. 4. Department of Radiology, Haydarpaşa Education and Research Hospital, Istanbul, Turkey. 5. Department of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey turgay.isbir@yeditepe.edu.tr tisbir@superonline.com.
Abstract
BACKGROUND: Prostate cancer is one of the most common solid tumors and the second leading cause of the death due to malignancy in men. Caspase 9 (CASP9) is a member of the intrinsic pathway and plays a central role in the apoptosis. PATIENTS AND METHODS: Genotyping of the CASP9 (rs1052576) polymorphism were performed using real-time polymerase chain reaction for blood samples of prostate cancer patients (n=69) and controls (n=76). RESULTS: There were no significant differences between the groups in the frequency of CASP9 genotypes (χ2=1.363; p=0.506). Patients with CASP9 (rs1052576) CT genotype were 12.8 fold higher in pathological stage of pT2a compared to any other stages of cancer (OR=0.078, 95% CI= 0.009-0.062; p=0.004). Also TT genotype carriers were 11.3 times lower in pathological stage of pT2a (OR=11.33, 95% CI=2.39-53.748; p=0.000). C allele carriers were 11.36 fold higher in pathological stage of pT2a compared to any other stages of cancer (OR=0.088, 95% CI=0.019-0.418; p=0.002). CONCLUSION: CASP9 (rs1052576) C allele was decreasing the risk for pathological stage of patients with prostate cancer and also CT genotype had positive impact on pathological stage of patients with prostate cancer. CASP9 (rs1052576) TT genotype was seemed to be associated with higher risk of pathological stage. Those results implicated that CASP9 variations could be associated with severity of prostate cancer. Copyright
BACKGROUND:Prostate cancer is one of the most common solid tumors and the second leading cause of the death due to malignancy in men. Caspase 9 (CASP9) is a member of the intrinsic pathway and plays a central role in the apoptosis. PATIENTS AND METHODS: Genotyping of the CASP9 (rs1052576) polymorphism were performed using real-time polymerase chain reaction for blood samples of prostate cancerpatients (n=69) and controls (n=76). RESULTS: There were no significant differences between the groups in the frequency of CASP9 genotypes (χ2=1.363; p=0.506). Patients with CASP9 (rs1052576) CT genotype were 12.8 fold higher in pathological stage of pT2a compared to any other stages of cancer (OR=0.078, 95% CI= 0.009-0.062; p=0.004). Also TT genotype carriers were 11.3 times lower in pathological stage of pT2a (OR=11.33, 95% CI=2.39-53.748; p=0.000). C allele carriers were 11.36 fold higher in pathological stage of pT2a compared to any other stages of cancer (OR=0.088, 95% CI=0.019-0.418; p=0.002). CONCLUSION:CASP9 (rs1052576) C allele was decreasing the risk for pathological stage of patients with prostate cancer and also CT genotype had positive impact on pathological stage of patients with prostate cancer. CASP9 (rs1052576) TT genotype was seemed to be associated with higher risk of pathological stage. Those results implicated that CASP9 variations could be associated with severity of prostate cancer. Copyright
Authors: Jiyoung Ahn; Adam S Kibel; Jong Y Park; Timothy R Rebbeck; Hanna Rennert; Janet L Stanford; Elaine A Ostrander; Stephen Chanock; Ming-Hsi Wang; Rama D Mittal; William B Isaacs; Elizabeth A Platz; Richard B Hayes Journal: Clin Cancer Res Date: 2011-02-22 Impact factor: 12.531
Authors: George E Theodoropoulos; Nikolaos V Michalopoulos; Malena P Pantou; Panagiota Kontogianni; Maria Gazouli; Theodoros Karantanos; Maria Lymperi; George C Zografos Journal: Cancer Genet Date: 2012-09-13